In line with our findings in ALL, a recent study also found heterogeneous sensitivity of diffuse large B-cell lymphoma cells to inhibitors of BCL-2, BCL-XL and MCL-1 [38]. Here, MCL1 is linked to acute lymphoblastic leukemia.